OLINC 600MG INJECTION 1X50S
THERAPEUTIC INDICATIONS:
OLINC is indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients. It is used in Upper respiratory infections, Lower respiratory infections, Skin and soft tissue infections, Bone and joint infections, Septicemia, endocarditis and Bacillary dysentery.
DOSAGE AND ADMINISTRATION:
Intramuscular
Adults:
For serious infections 600 mg (2 mL) intramuscularly every 24 hours. For more severe infections 600 mg (2 mL) intramuscularly every 12 hours or more often.
Pediatric patients over 1 month of age:
For serious infections one intramuscular injection of 10 mg/kg every 24 hours. For more severe infections one intramuscular injection of 10 mg/kg every 12 hours or more often.
Intravenous:
Adults:
The intravenous dose will be determined by the severity of the infection. For serious infections doses of 600 mg of lincomycin (2 mL of OLINC) to 1 gram are given every 8 to 12 hours. For more severe infections these doses may have to be increased. In life-threatening situations daily intravenous doses of as much as 8 grams have been given. Intravenous doses are given on the basis of 1 gram of lincomycin diluted in not less than 100 mL.
Pediatric patients over 1 month of age:
10 to 20 mg/kg/day depending on the severity of the infection may be infused in divided doses as described above for adults.
Safety and effectiveness in pediatric patients below the age of one month have not been established.
Subconjunctival Injection:
0.25 mL (75 mg) injected subconjunctivally will result in ocular fluid concentrations of antibacterial (lasting for at least 5 hours) sufficient for most susceptible pathogens.
Patients with Renal Impairment:
An appropriate dose is 25 to 30% of that recommended for patients with normally functioning kidneys.
CONTRAINDICATIONS:
This drug is contraindicated in patients previously found to be hypersensitive to lincomycin or clindamycin.
WARNINGS AND PRECAUTIONS:
OLINC should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis. OLINC should be used with caution in patients with a history of asthma or significant allergies. Severe cardiopulmonary reactions have occurred when this drug has been given at greater than the recommended concentration and rate.
DRUG INTERACTIONS:
Lincomycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, it should be used in caution in patients receiving such agents.
ADVERSE EFFECTS:
Gastrointestinal disorders: Diarrhea, nausea, vomiting, glossitis, stomatitis, abdominal pain, abdominal discomfort, anal pruritus.
INCOMPATIBILITIES
When combined with lincomycin in an infusion solution, novobiocin, kanamycin, and phenytoin are each physically incompatible with lincomycin.
OVERDOSE:
Serum concentrations of lincomycin are not appreciably affected by hemodialysis and peritoneal dialysis.
SHELF LIFE:
OLINC Injection and Capsules: 3 Years
THERAPEUTIC INDICATIONS:
OLINC is indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients. It is used in Upper respiratory infections, Lower respiratory infections, Skin and soft tissue infections, Bone and joint infections, Septicemia, endocarditis and Bacillary dysentery.
DOSAGE AND ADMINISTRATION:
Intramuscular
Adults:
For serious infections 600 mg (2 mL) intramuscularly every 24 hours. For more severe infections 600 mg (2 mL) intramuscularly every 12 hours or more often.
Pediatric patients over 1 month of age:
For serious infections one intramuscular injection of 10 mg/kg every 24 hours. For more severe infections one intramuscular injection of 10 mg/kg every 12 hours or more often.
Intravenous:
Adults:
The intravenous dose will be determined by the severity of the infection. For serious infections doses of 600 mg of lincomycin (2 mL of OLINC) to 1 gram are given every 8 to 12 hours. For more severe infections these doses may have to be increased. In life-threatening situations daily intravenous doses of as much as 8 grams have been given. Intravenous doses are given on the basis of 1 gram of lincomycin diluted in not less than 100 mL.
Pediatric patients over 1 month of age:
10 to 20 mg/kg/day depending on the severity of the infection may be infused in divided doses as described above for adults.
Safety and effectiveness in pediatric patients below the age of one month have not been established.
Subconjunctival Injection:
0.25 mL (75 mg) injected subconjunctivally will result in ocular fluid concentrations of antibacterial (lasting for at least 5 hours) sufficient for most susceptible pathogens.
Patients with Renal Impairment:
An appropriate dose is 25 to 30% of that recommended for patients with normally functioning kidneys.
CONTRAINDICATIONS:
This drug is contraindicated in patients previously found to be hypersensitive to lincomycin or clindamycin.
WARNINGS AND PRECAUTIONS:
OLINC should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis. OLINC should be used with caution in patients with a history of asthma or significant allergies. Severe cardiopulmonary reactions have occurred when this drug has been given at greater than the recommended concentration and rate.
DRUG INTERACTIONS:
Lincomycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, it should be used in caution in patients receiving such agents.
ADVERSE EFFECTS:
Gastrointestinal disorders: Diarrhea, nausea, vomiting, glossitis, stomatitis, abdominal pain, abdominal discomfort, anal pruritus.
INCOMPATIBILITIES
When combined with lincomycin in an infusion solution, novobiocin, kanamycin, and phenytoin are each physically incompatible with lincomycin.
OVERDOSE:
Serum concentrations of lincomycin are not appreciably affected by hemodialysis and peritoneal dialysis.
SHELF LIFE:
OLINC Injection and Capsules: 3 Years
or 
